Ian Chau Selected Research

Ramucirumab

1/2021	Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC.
10/2020	Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial.
1/2020	Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials.
3/2019	Ramucirumab and its use in the treatment of hepatocellular carcinoma.
1/2019	Targeting Vascular Endothelial Growth Factor in Oesophagogastric Cancer: A Review of Progress to Date and Immunotherapy Combination Strategies.
1/2019	Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial.
1/2019	Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
1/2019	Association of quality of life with disease characteristics and treatment outcomes in patients with advanced gastric cancer: Exploratory analysis of RAINBOW and REGARD phase III trials.
12/2018	Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF).
4/2018	Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ian Chau Research Topics

Disease

101	Neoplasms (Cancer) 01/2022 - 04/2002
40	Colorectal Neoplasms (Colorectal Cancer) 05/2022 - 01/2002
27	Adenocarcinoma 01/2022 - 06/2008
23	Stomach Neoplasms (Stomach Cancer) 01/2022 - 11/2007
20	Disease Progression 01/2022 - 08/2003
18	Rectal Neoplasms (Rectal Cancer) 01/2020 - 01/2002
13	Neoplasm Metastasis (Metastasis) 12/2021 - 02/2003
10	Pancreatic Neoplasms (Pancreatic Cancer) 11/2021 - 07/2002
7	Carcinoma (Carcinomatosis) 01/2022 - 09/2010
7	Hepatocellular Carcinoma (Hepatoma) 01/2020 - 07/2015
6	Lymphoma (Lymphomas) 01/2022 - 09/2002
6	Hypertension (High Blood Pressure) 10/2020 - 01/2014
5	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2021 - 04/2007
4	Hodgkin Disease (Hodgkin's Disease) 01/2022 - 09/2002
4	Microsatellite Instability 08/2021 - 01/2020
4	Infections 05/2020 - 07/2002
4	Colonic Neoplasms (Colon Cancer) 01/2020 - 01/2002
4	Melanoma (Melanoma, Malignant) 01/2020 - 08/2015
4	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 10/2019 - 02/2003
4	Neutropenia 01/2019 - 07/2002
3	Pain (Aches) 01/2020 - 01/2014
3	Vomiting 01/2019 - 01/2014
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2019 - 08/2015
3	Ovarian Neoplasms (Ovarian Cancer) 11/2018 - 01/2011
3	Breast Neoplasms (Breast Cancer) 07/2018 - 01/2011
3	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 05/2018 - 02/2007
3	Non-Hodgkin Lymphoma (Lymphosarcoma) 02/2007 - 09/2002
2	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2022 - 01/2017
2	Cardiotoxicity 12/2021 - 10/2018
2	Cytokine Release Syndrome 12/2021 - 01/2021
2	COVID-19 12/2021 - 01/2021
2	Thrombocytopenia (Thrombopenia) 01/2021 - 07/2015
2	Sepsis (Septicemia) 05/2020 - 01/2020
2	Deglutition Disorders (Dysphagia) 01/2020 - 01/2014
2	Colitis 01/2019 - 02/2006
2	Sudden Death 01/2019 - 02/2006
2	Abdominal Pain (Pain, Abdominal) 01/2019 - 01/2014

Drug/Important Bio-Agent (IBA)

23	Biomarkers (Surrogate Marker)IBA 08/2021 - 02/2003
22	RamucirumabIBA 01/2021 - 01/2014
17	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2022 - 01/2002
15	Fluorouracil (Carac)FDA LinkGeneric 01/2022 - 07/2002
12	Irinotecan (Camptosar)FDA LinkGeneric 11/2021 - 01/2002
12	Cetuximab (Erbitux)FDA Link 01/2021 - 07/2004
12	Capecitabine (Xeloda)FDA Link 01/2016 - 01/2004
11	PlatinumIBA 01/2019 - 05/2011
11	Gemcitabine FDA Link 12/2018 - 09/2002
9	Cisplatin (Platino)FDA LinkGeneric 01/2019 - 03/2003
8	Leucovorin (Folinic Acid)FDA Link 01/2022 - 05/2003
8	pembrolizumabIBA 01/2022 - 12/2018
8	Monoclonal AntibodiesIBA 01/2022 - 04/2011
8	Trastuzumab (Herceptin)FDA Link 01/2022 - 11/2010
7	ErbB Receptors (EGF Receptor)IBA 04/2022 - 01/2002
7	NivolumabIBA 01/2022 - 07/2016
7	Pharmaceutical PreparationsIBA 12/2018 - 01/2014
6	Paclitaxel (Taxol)FDA LinkGeneric 01/2022 - 01/2014
6	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 11/2013
6	Immune Checkpoint InhibitorsIBA 01/2021 - 10/2017
6	Panitumumab (Vectibix)FDA Link 01/2021 - 09/2010
6	VemurafenibIBA 01/2020 - 08/2015
6	Biological ProductsIBA 11/2019 - 11/2007
5	IpilimumabIBA 01/2022 - 07/2016
5	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2019 - 11/2009
5	Methylprednisolone FDA LinkGeneric 05/2018 - 03/2003
4	afliberceptIBA 05/2022 - 08/2014
4	B7-H1 AntigenIBA 01/2022 - 10/2018
4	Docetaxel (Taxotere)FDA Link 01/2022 - 05/2011
4	folfirinoxIBA 11/2021 - 12/2014
4	AntibodiesIBA 01/2021 - 07/2013
4	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 01/2019 - 01/2014
3	Angiogenesis InhibitorsIBA 05/2022 - 01/2014
3	ibrutinibIBA 01/2022 - 10/2018
3	VaccinesIBA 12/2021 - 10/2016
3	MicroRNAs (MicroRNA)IBA 11/2021 - 01/2016
3	Calcibiotic Root Canal SealerIBA 01/2021 - 01/2019
3	Aspartate Aminotransferases (Aspartate Transaminase)IBA 10/2020 - 07/2015
3	Bevacizumab (Avastin)FDA Link 12/2019 - 11/2009
3	Phosphotransferases (Kinase)IBA 10/2018 - 01/2016
3	Sorafenib (BAY 43-9006)FDA Link 01/2018 - 07/2015
3	Rituximab (Mabthera)FDA Link 01/2017 - 04/2007
3	Matrix Metalloproteinases (MMPs)IBA 01/2017 - 01/2002
2	human ERBB2 proteinIBA 04/2022 - 07/2018
2	regorafenibIBA 12/2021 - 01/2018
2	Neutralizing AntibodiesIBA 12/2021 - 12/2021
2	Choline (Choline Chloride)IBA 10/2021 - 01/2021
2	alpha-Fetoproteins (alpha-Fetoprotein)IBA 01/2020 - 01/2018
2	Circulating Tumor DNAIBA 01/2020 - 01/2016
2	Fetal Proteins (Fetoprotein)IBA 03/2019 - 02/2017
2	AntigensIBA 01/2019 - 04/2004
2	raltitrexed (D 1694)IBA 01/2019 - 01/2002

Therapy/Procedure

70	Therapeutics 05/2022 - 01/2002
65	Drug Therapy (Chemotherapy) 01/2022 - 01/2002
14	Radiotherapy 01/2022 - 01/2002
10	Neoadjuvant Therapy 01/2017 - 06/2008
9	Chemoradiotherapy 01/2020 - 02/2006
8	Immunotherapy 06/2021 - 12/2015
8	Adjuvant Chemotherapy 01/2020 - 10/2002
5	Combination Drug Therapy (Combination Chemotherapy) 08/2021 - 09/2002
4	Aftercare (After-Treatment) 01/2022 - 01/2014
3	Salvage Therapy 01/2020 - 03/2003
2	Stem Cell Transplantation 01/2022 - 01/2017